An international research team described a giant bacteriophage that effectively attacks metallo‑β‑lactamase producing strains of Pseudomonas aeruginosa, a pathogen notorious for multidrug resistance. The study, led by Paranos, Skliros and Zrelovs, characterized phage biology and in‑vitro efficacy against clinical isolates, presenting a potential alternative or adjunct to small‑molecule antibiotics. Phage therapy uses bacterial viruses to lyse pathogens; these findings support translational work toward compassionate‑use or trial frameworks for resistant infections.